Resverlogix Corp
TSX:RVX
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Resverlogix Corp
TSX:RVX
|
CA |
|
C
|
Cerence Inc
F:0S6
|
US |
|
S
|
Saf-Holland Se
DUS:SFQ
|
DE |
|
B
|
Bper Banca SpA
XBER:4BE
|
IT |
|
Quadient SA
OTC:NPACY
|
FR |
|
I
|
Intchains Group Ltd
NASDAQ:ICG
|
CN |
|
H
|
Honeywell International Inc
XHAM:ALD
|
US |
|
I
|
ImmunoGen Inc
XBER:IMU
|
US |
|
V
|
Veolia Environnement SA
DUS:VVD
|
FR |
|
K
|
KLA Corp
XBER:KLA
|
US |
Resverlogix Corp
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
